Strategy's stock, MSTR, has skyrocketed to an all-time high of $410.81 on July 31, closing at $401.86 in an astonishing rally. The stock is currently up 3,749.23% from its debut in 1998. It appears to be higher on substantial volume today following the company's extraordinary second-quarter earnings report.

Health care stocks sank after the White House released letters asking big pharmaceutical companies to cut prices and make other changes in the next 60 days. Eli Lilly & Co. fell 2.6%, UnitedHealth Group slid 6.2% and Bristol-Myers Squibb dropped 5.8%.

If the company’s core business continues growing at the current rate and its Superintelligence efforts gain traction, “there’s no telling what the ceiling is for Meta,” Bernstein analysts said.